{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:28:20Z","timestamp":1780446500669,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to assess the efficacy and safety of esaxerenone (CS-3150) in treating primary hypertension. PubMed (Medline), Cochrane Central Register of Controlled Trials (CENTRAL), and Embase databases were searched for articles published until April 18, 2023. The outcomes included were diastolic blood pressure (DBP), systolic blood pressure (SBP), 24\u2009h DBP, 24\u2009h SBP, and adverse events. The meta-analysis was conducted using RevMan 5.3. This study included three trials. CS-3150 5\u2009mg had a greater effect on lowering the SBP, DBP, 24\u2009h SBP, and 24\u2009h DBP than either CS-3150 2.5\u2009mg or eplerenone 50\u2009mg. In contrast, CS-3150 2.5\u2009mg and eplerenone 50\u2009mg showed no significant difference in lowering DBP, SBP, 24\u2009h DBP, and 24\u2009h SBP. Moreover, adverse events occurred at comparable rates in the three groups. CS-3150 (especially CS-3150 5\u2009mg) is an effective and safe treatment for primary hypertension; which can reduce blood pressure and alleviate hypertensive symptoms.<\/jats:p>","DOI":"10.1038\/s41371-023-00889-9","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T12:02:59Z","timestamp":1704369779000},"page":"102-109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of esaxerenone (CS-3150) in primary hypertension: a meta-analysis"],"prefix":"10.1038","volume":"38","author":[{"given":"Ran","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8381-3781","authenticated-orcid":false,"given":"Xiaoxia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"889_CR1","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/dom.13248","volume":"20","author":"LF Buckley","year":"2018","unstructured":"Buckley LF, Dixon DL, Wohlford GFT, Wijesinghe DS, Baker WL, Van Tassell BW. Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: A subgroup analysis of high-risk ACCORDION trial participants. Diabetes Obes Metab. 2018;20:1499\u2013502.","journal-title":"Diabetes Obes Metab"},{"key":"889_CR2","doi-asserted-by":"publisher","first-page":"6657003","DOI":"10.1155\/2021\/6657003","volume":"2021","author":"A Mohammed Nawi","year":"2021","unstructured":"Mohammed Nawi A, Mohammad Z, Jetly K, Abd Razak MA, Ramli NS, Wan Ibadullah WAH, et al. The prevalence and risk factors of hypertension among the urban population in southeast asian countries: a systematic review and meta-analysis. Int J Hypertens. 2021;2021:6657003.","journal-title":"Int J Hypertens"},{"key":"889_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","volume":"365","author":"PM Kearney","year":"2005","unstructured":"Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217\u201323.","journal-title":"Lancet"},{"key":"889_CR4","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1053\/j.ajkd.2009.06.044","volume":"55","author":"BV Mittal","year":"2010","unstructured":"Mittal BV, Singh AK. Hypertension in the developing world: challenges and opportunities. Am J Kidney Dis. 2010;55:590\u20138.","journal-title":"Am J Kidney Dis"},{"key":"889_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40292-017-0245-9","volume":"25","author":"RM Bruno","year":"2018","unstructured":"Bruno RM, Masi S, Taddei M, Taddei S, Virdis A. Essential hypertension and functional microvascular ageing. High Blood Press Cardiovasc Prev. 2018;25:35\u201340.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"889_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/VHRM.S138599","volume":"13","author":"JC Yugar-Toledo","year":"2017","unstructured":"Yugar-Toledo JC, Modolo R, de Faria AP, Moreno H. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists. Vasc Health Risk Manag. 2017;13:403\u201311.","journal-title":"Vasc Health Risk Manag"},{"key":"889_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1042\/CS20171454","volume":"132","author":"Z Gurel","year":"2018","unstructured":"Gurel Z, Sheibani N. O-Linked \u03b2-N-acetylglucosamine (O-GlcNAc) modification: a new pathway to decode pathogenesis of diabetic retinopathy. Clin Sci (Lond). 2018;132:185\u201398.","journal-title":"Clin Sci (Lond)"},{"key":"889_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11906-019-0924-0","volume":"21","author":"AA Manolis","year":"2019","unstructured":"Manolis AA, Manolis TA, Melita H, Manolis AS. Eplerenone versus spironolactone in resistant hypertension: an efficacy and\/or cost or just a men\u2019s issue? Curr Hypertens Rep. 2019;21:22.","journal-title":"Curr Hypertens Rep"},{"key":"889_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/hr.2012.182","volume":"36","author":"A Sato","year":"2013","unstructured":"Sato A. Mineralocorticoid receptor antagonists: their use and differentiation in Japan. Hypertens Res. 2013;36:185\u201390.","journal-title":"Hypertens Res"},{"key":"889_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","volume":"200","author":"M Lainscak","year":"2015","unstructured":"Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, et al. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. Int J Cardiol. 2015;200:25\u20139.","journal-title":"Int J Cardiol"},{"key":"889_CR11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1124\/dmd.118.084897","volume":"47","author":"M Yamada","year":"2019","unstructured":"Yamada M, Mendell J, Takakusa H, Shimizu T, Ando O. Pharmacokinetics, Metabolism, and Excretion of [(14)C]Esaxerenone, a novel mineralocorticoid receptor blocker in humans. Drug Metab Dispos. 2019;47:340\u201349.","journal-title":"Drug Metab Dispos"},{"key":"889_CR12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","volume":"761","author":"K Arai","year":"2015","unstructured":"Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharmacol. 2015;761:226\u201334.","journal-title":"Eur J Pharmacol"},{"key":"889_CR13","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41371-019-0207-x","volume":"33","author":"S Ito","year":"2019","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yamakawa S. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study. J Hum Hypertens. 2019;33:542\u201351.","journal-title":"J Hum Hypertens"},{"key":"889_CR14","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76:2982\u20133021.","journal-title":"J Am Coll Cardiol"},{"key":"889_CR15","doi-asserted-by":"publisher","first-page":"e25572","DOI":"10.1097\/MD.0000000000025572","volume":"100","author":"J Yu","year":"2021","unstructured":"Yu J, Wei Y, Jing Y, Gao Y. Effect of acupuncture on essential hypertension: A protocol for systematic review and meta-analysis. Medicine. 2021;100:e25572.","journal-title":"Medicine"},{"key":"889_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2471\/BLT.08.057885","volume":"88","author":"S Capewell","year":"2010","unstructured":"Capewell S, Ford ES, Croft JB, Critchley JA, Greenlund KJ, Labarthe DR. Cardiovascular risk factor trends and potential for reducing coronary heart disease mortality in the United States of America. Bull World Health Organ. 2010;88:120\u201330.","journal-title":"Bull World Health Organ"},{"key":"889_CR17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1097\/00004872-200405000-00001","volume":"22","author":"NM Kapan","year":"2004","unstructured":"Kapan NM. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens. 2004;22:863\u20139.","journal-title":"J Hypertens"},{"key":"889_CR18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.4183\/aeb.2020.487","volume":"16","author":"E B\u0103dil\u0103","year":"2020","unstructured":"B\u0103dil\u0103 E. The expanding class of mineralocorticoid receptor modulators: New ligands for kidney, cardiac, vascular, systemic and behavioral selective actions. Acta Endocrinol (Buchar). 2020;16:487.","journal-title":"Acta Endocrinol (Buchar)"},{"key":"889_CR19","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1210\/en.2005-1318","volume":"147","author":"TA Williams","year":"2006","unstructured":"Williams TA, Verhovez A, Milan A, Veglio F, Mulatero P. Protective effect of spironolactone on endothelial cell apoptosis. Endocrinology. 2006;147:2496\u20132505.","journal-title":"Endocrinology"},{"key":"889_CR20","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1021\/cr020456u","volume":"105","author":"W Gao","year":"2005","unstructured":"Gao W, Bohl CE, Dalton JT. Chemistry and structural biology of androgen receptor. Chem Rev. 2005;105:3352\u201370.","journal-title":"Chem Rev"},{"key":"889_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. The New England journal of medicine. 2011;364:11\u201321.","journal-title":"The New England journal of medicine"},{"key":"889_CR22","doi-asserted-by":"crossref","unstructured":"Funder JW. Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr Blood Press Control 2013:129\u201338.","DOI":"10.2147\/IBPC.S13783"},{"key":"889_CR23","doi-asserted-by":"publisher","first-page":"381","DOI":"10.4103\/JPBS.JPBS_338_19","volume":"12","author":"A Pradhan","year":"2020","unstructured":"Pradhan A, Vohra S, Sethi R. Eplerenone: the multifaceted drug in cardiovascular pharmacology. J Pharm Bioall Sci. 2020;12:381\u201390.","journal-title":"J Pharm Bioall Sci"},{"key":"889_CR24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41440-020-00569-y","volume":"44","author":"H Rakugi","year":"2021","unstructured":"Rakugi H, Yamakawa S, Sugimoto K. Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone. Hypertens Res. 2021;44:371\u201385.","journal-title":"Hypertens Res"},{"key":"889_CR25","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41440-020-00585-y","volume":"44","author":"S Ito","year":"2021","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Iijima S. Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction. Hypertens Res. 2021;44:489\u201397.","journal-title":"Hypertens Res"},{"key":"889_CR26","doi-asserted-by":"publisher","first-page":"100951","DOI":"10.1016\/j.cegh.2021.100951","volume":"13","author":"ZD Kifle","year":"2022","unstructured":"Kifle ZD, Adugna M, Chanie GS, Mohammed A. Prevalence and associated factors of hypertension complications among hypertensive patients at University of Gondar Comprehensive Specialized Referral Hospital. Clin Epidemiol Glob. 2022;13:100951.","journal-title":"Clin Epidemiol Glob"},{"key":"889_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41440-021-00756-5","volume":"45","author":"K Kario","year":"2022","unstructured":"Kario K, Ito S, Itoh H, Rakugi H, Okuda Y, Yamakawa S. Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes. Hypertens Res. 2022;45:97\u2013105.","journal-title":"Hypertens Res"},{"key":"889_CR28","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/jama.2023.16029","volume":"330","author":"LJ Laffin","year":"2023","unstructured":"Laffin LJ, Rodman D, Luther JM, Vaidya A, Weir MR, Rajicic N, et al. Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial. Jama. 2023;330:1140\u201350.","journal-title":"Jama"},{"key":"889_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41440-022-01070-4","volume":"46","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, Bond M, Murphy B, Hui J, Isaacsohn J. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. Hypertens Res: Offic J Jpn Soc Hypertens. 2023;46:108\u201318.","journal-title":"Hypertens Res: Offic J Jpn Soc Hypertens"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-023-00889-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-023-00889-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-023-00889-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T08:03:56Z","timestamp":1707120236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-023-00889-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["889"],"URL":"https:\/\/doi.org\/10.1038\/s41371-023-00889-9","relation":{},"ISSN":["1476-5527"],"issn-type":[{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"assertion":[{"value":"18 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was not required, because this is a meta-analysis and no human involved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}